Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC‐targeting protein. Issue 10 (29th April 2016)

• Record Type: Journal Article
• Authors: Wang, Y.; Wu, S.; Wang, Z. C.; Zhu, X. M.; Yin, X. T.; Gao, K.; Du, Z. Y.; Chen, G. Z.; Yu, J. Y.
• Is Part Of: Journal of viral hepatitis. Volume 23:Issue 10(2016)
• Page Start: 798
• Page End: 804
• Publication Date: 2016-04-29
• Subjects: DC‐targeting protein -- HBV DNA vaccine -- immunogenicity; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12542
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: DNA vaccine targeting delivery to DC represents one effective strategy to improve the immunogenicity of the vaccine. In a previous study, we developed a novel DC‐targeting recombinant protein that can deliver plasmid DNA to DCs by an electrostatic coupling effect and can thus improve the uptake efficiency of DCs, improving the expression of plasmid DNA in DCs. In this study, we coupled the protein with the HBV DNA vaccine pSVK‐HBVA and investigated whether the immunogenicity and antiviral ability of the vaccine can be improved in HBV transgenic mice. The results show that a stronger specific immune response can be induced in mice after immunization with the coupling vaccine. The HBV DNA copy number and circulating antigen HBsAg in the serum of HBV transgenic mice were significantly decreased. Therefore, this study has demonstrated that the DC‐targeting protein has the ability to improve the immunogenicity and the antiviral activity of the HBV DNA vaccine pSVK‐HBVA. These findings indicate that this DC‐targeting protein can be a potential method for the delivery of DNA vaccines directly to DCs.